Australia markets closed

Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
48.28-0.84 (-1.71%)
At close: 04:00PM EDT
48.38 +0.10 (+0.21%)
After hours: 07:59PM EDT

Bristol-Myers Squibb Company

Route 206 & Province Line Road
Princeton, NJ 08543
United States
609 252 4621
https://www.bms.com

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees34,100

Key executives

NameTitlePayExercisedYear born
Dr. Christopher S. Boerner Ph.D.CEO & Chairman3.14MN/A1971
Mr. David V. ElkinsExecutive VP & CFO2.28MN/A1968
Ms. Sandra Leung Esq.Executive VP & General Counsel2.58MN/A1961
Mr. Samit Hirawat M.D.Executive VP, Chief Medical Officer & Head of Development2.62MN/A1969
Mr. Greg MeyersExecutive VP and Chief Digital & Technology OfficerN/AN/A1973
Mr. Timothy PowerVP & Head of Investor RelationsN/AN/AN/A
Ms. Kimberly M. JablonskiChief Compliance & Ethics OfficerN/AN/AN/A
Ms. Ahn Amanda PooleExecutive Vice President & Chief Human Resources OfficerN/AN/A1975
Dr. Joseph J. Eiden Jr.Head of Medical AffairsN/AN/A1949
Mr. Adam LenkowskyExecutive VP, Chief Commercialization Officer & Head of U.S. OncologyN/AN/A1972
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Corporate governance

Bristol-Myers Squibb Company’s ISS governance QualityScore as of 1 April 2024 is 2. The pillar scores are Audit: 5; Board: 6; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.